| Bioactivity | INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 induces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research[1]. |
| Target | CDK2. |
| Name | INX-315 |
| CAS | 2745060-92-6 |
| Formula | C19H21N7O3S |
| Molar Mass | 427.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dietrich C, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2023 Dec 4. |
INX-315
CAS: 2745060-92-6 F: C19H21N7O3S W: 427.48
INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 induces
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.